Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi (IST:GENIL)

Market Cap	43.38B
Revenue (ttm)	14.74B
Net Income (ttm)	148.68M
Shares Out	300.00M
EPS (ttm)	0.50
PE Ratio	291.77
Forward PE	n/a
Dividend	1.11 (0.77%)
Ex-Dividend Date	Oct 8, 2024

Volume	957,454
Average Volume	891,326
Open	137.70
Previous Close	135.80
Day's Range	134.70 - 145.40
52-Week Range	54.20 - 166.50
Beta	1.04
RSI	55.49
Earnings Date	May 7, 2025

About IST:GENIL

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. The company was incorporated in 1...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 619
• Stock Exchange: Istanbul Stock Exchange
• Ticker Symbol: GENIL

Financial Performance

In 2024, IST:GENIL's revenue was 14.74 billion, an increase of 25.25% compared to the previous year's 11.77 billion. Earnings were 148.68 million, a decrease of -77.35%.